Silence Therapeutics plc
HealthcareNASDAQ:SLN · NASDAQ Global Market
+$0.01 today
Vol 0.24M · Avg 0.31M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $5.7M |
| Short-term Investments | $64.4M |
| Receivables | $22.2M |
| Other Current | $10.6M |
| Total Current Assets | $102.9M |
| PP&E (Net) | $1.5M |
| Goodwill | $10.4M |
| Intangible Assets | $248.0K |
| Other Non-current | $127.0K |
| Total Non-current Assets | $12.3M |
| Total Assets | $115.1M |
Analysis
Selected assets total $115.1M for Latest. The largest visible component is Short-term Investments at $64.4M, about 56.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.3M -88.4% | $97.0M +40.9% | $68.8M +25.5% | $54.8M -25.5% | $73.5M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $73.8M +255.3% | $20.8M | $0 -100.0% | $16.3M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $24.6M +14.5% | $21.5M -10.3% | $24.0M +2520.4% | $915.0K +176.4% | $331.0K | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $0 | $0 | $0 -100.0% | $16.4M +101.4% | $8.2M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $118.7M -20.7% | $149.7M +45.1% | $103.2M +6.7% | $96.7M +12.0% | $86.3M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $1.7M +10.8% | $1.6M -31.6% | $2.3M +4.9% | $2.2M +13.2% | $1.9M | $1.2B | $1.5B | $687.8M |
| Goodwill | $10.6M +41.5% | $7.5M -24.8% | $10.0M +24.6% | $8.0M +5.5% | $7.6M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $288.0K +15.5% | $249.3K -31.1% | $362.0K +13.1% | $320.0K +1233.3% | $24.0K | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 -100.0% | $284.0K -5.6% | $301.0K | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $127.0K -95.6% | $2.9M -21.3% | $3.6M | $0 | $0 | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $12.8M +4.8% | $12.2M -25.1% | $16.3M +50.7% | $10.8M +9.7% | $9.9M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $131.4M -18.8% | $161.9M +35.6% | $119.4M +11.1% | $107.5M +11.8% | $96.2M | $13.3B | $11.9B | $10.6B |
| Account Payables | $4.4M +49.2% | $3.0M -11.8% | $3.3M +5.1% | $3.2M -21.6% | $4.1M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $89.0K | $0 -100.0% | $228.0K | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $716.0K +50.6% | $475.5K | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $168.0K -31.3% | $244.5K -96.3% | $6.6M | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $5.9M +115.9% | $2.8M -67.9% | $8.6M -9.2% | $9.5M +113.3% | $4.4M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $13.6M +1.3% | $13.4M -39.8% | $22.3M +1.8% | $21.9M +44.7% | $15.2M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $55.5M +34.0% | $41.4M -44.8% | $75.0M | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 -100.0% | $63.5M -12.4% | $72.5M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $55.5M +34.2% | $41.4M -44.9% | $75.1M +18.3% | $63.5M -12.4% | $72.5M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $69.1M +26.1% | $54.8M -43.7% | $97.5M +14.1% | $85.4M -2.6% | $87.7M | $14.7B | $3.7B | $9.6B |
| Common Stock | $10.3M +25.2% | $8.2M -7.1% | $8.8M +64.1% | $5.4M +20.1% | $4.5M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$562.6M -48.5% | -$378.8M +12.3% | -$431.9M -64.1% | -$263.3M -18.1% | -$223.0M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$3.0M +68.4% | -$9.4M -123.3% | $40.4M -24.2% | $53.3M +24.9% | $42.7M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 +100.0% | -$51.1M | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $62.3M -41.8% | $107.1M +387.0% | $22.0M -0.4% | $22.1M +158.9% | $8.5M | $9.1B | $7.7B | $3.3B |
| Total Debt | $160.0K +71.1% | $93.5K -73.0% | $346.0K -22.4% | $446.0K +225.5% | $137.0K | $724.2M | $410.6M | $399.4M |
| Net Debt | -$11.1M +88.5% | -$96.9M -41.5% | -$68.4M -25.9% | -$54.4M +25.9% | -$73.4M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$444.15M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$106.17M
Mereo BioPharma Group plc
MREO
$48.68M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does SLN have?
Silence Therapeutics plc (SLN) reported $11.28M in cash and equivalents in fiscal 2025.
How much debt does SLN carry?
Silence Therapeutics plc (SLN) reported $160,000.00 of total debt, with net debt of -$11,117,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.